To evaluate the add-on effect of Eladi Modak (10 grams)along with Phenytoin and Lorazepam in 37 (male and female) participants aged 25 to 50 years diagnosed with Alcohol Withdrawal Syndrome.

Randomised Control Trial on the add-on effect of Eladi Modak with Phenytoin and Lorazepam in Alcohol Withdrawal Syndrome. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087541

Enrollment

Registered

2025-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Having any of the two maladaptive patterns of alcohol consumption mentioned in DSM-5 of alcohol use disorder. Suffering from alcohol withdrawal syndrome.

Exclusion criteria

Exclusion criteria: Participants suffering from other systemic disorders. Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame
Comparative efficacy of Eladi Modak as an add on to Phenytoin and Lorazepam versus standard treatment alone, measured by change in CIWA-Ar scoreTimepoint: with a gap of 7 days for 28 days	—

Secondary

Measure	Time frame
Changes in CIWA-Ar score in patients of alcohol withdrawal syndrome in both groupsTimepoint: 28 days	—

Countries

India

Contacts

Public ContactSakina Kapadia

Tilak Ayurved Mahavidyalaya

dr.rohaan@gmail.com9405680411

Outcome results